November 21, 2024
- Our Services
- Platforms
- Target Solutions
- Technologies
- Service Types
- Our Science
- About Us
- Contact us
From conventional cell lines to CDX, to patient-derived xenograft (PDX) and organoid models, we have the widest range of oncology model systems available today. Whether you’re in the discovery, preclinical or translational phase of drug development, the Crown Bioscience team will partner you need to advance your oncology molecule.
Built upon a solid foundation of oncology experts and quality standards that surpass operational need, our facilities in the USA, China and Europe are strategically located to serve all major research markets. This enables our industry leading response times to initiate studies in days, not weeks, and for our customers to partner with study managers in any location.
Combining innovation with breadth, depth, and capacity, we deliver the world’s premier Translational Oncology Drug Discovery Platforms helping our customers to increase successful clinical candidates.
Whatever your project needs, we have the in vitro biology platform to support faster, better decision-making for your oncology drug discovery program.
Our expert team have extensive experience of working with companies to support the in vitro pharmacology characterization of lead compounds and are committed to saving you precious time and resources by providing efficient screening platforms and validated 2D and 3D models, giving you confidence in your data.
Utilize the XenoBase®, the world’s largest commercial database of well-characterized cell lines to choose the correct cell lines for in vitro evaluation of your novel molecules.
Incorporate the most translatable 3D in vitro models available into your oncology drug development programs with our exclusive Hubrecht Organoid Technology (HUB) licence.
Use cost-effective, rapid, and large-scale cancer cell line screening to advance your lead compound to validated candidate
Detect more than 500 different morphological parameters of 3D in vitro models using our powerful high content screening services
With an industry-leading 3000 PDX models available, we are committed to advancing your preclinical development programs in a timely and cost-effective manner.
Partner with us to select the most appropriate platform, study design, and screening method tailored to each of your individual drug candidates and research question. Each of our models are supported by a range of translational tools including biomarker, in vitro/ex vivo assays, and in silico modelling to optimize lead candidates.
Leverage our unrivalled collection of PDX models, derived directly from patient tumors to reflect the heterogeneity and diversity of the human patient population
Make key decisions in a timely and cost-effective manner about the progression of your preclinical development program with cell line-derived xenograft (CDX) models.
